Want to see GERN full AI Analyst Report?
GERN Stock Chart & Stats
$1.42
$0.09(6.34%)
At close: 4:00 PM EDT
$1.42
$0.09(6.34%)
Day’s Range― - ―
52-Week Range$1.04 - $2.01
Previous CloseN/A
Volume230.62K
Average Volume (3M)10.91M
Market Cap
$827.56M
Enterprise Value$934.92
Total Cash (Recent Filing)$314.29M
Total Debt (Recent Filing)$251.84M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 05, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding641,521,000
10 Day Avg. Volume6,024,829
30 Day Avg. Volume10,908,346
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside181.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$234.24M
Bulls Say, Bears Say
Bulls Say
Revenue And Commercial TractionQ1 2026 revenue growth (31% YoY), sequential demand growth and ~1,450 prescribing accounts indicate durable commercial adoption. Expanding prescriber base and recurring patient starts support revenue scale, improving predictability and the potential to convert scale into longer-term cash generation.
Clinical Program Progress And ValidationFull Phase III enrollment, an H2 2026 interim, peer-reviewed publications and NCCN chemotherapy order-template inclusion materially de-risk development. Positive clinical validation strengthens label credibility, supports broader adoption, payer engagement and partnership opportunities over multiple years.
Balance Sheet Cushion And Manageable LeverageA meaningful equity cushion and moderate assets, with debt that appears manageable, give the company financial optionality. This supports ongoing commercialization and CMC investments, provides runway to pursue milestones, and reduces immediate solvency pressure while losses are being addressed.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$126M TTM) and a notable quarter cash decline force reliance on existing liquidity or external financing. This dynamic can limit strategic flexibility, increase dilution risk, and constrain the pace of commercial expansion or additional clinical investment.
Widening Gross-to-Net PressureA structural rise in gross-to-net (21% from 13%) and expectations for low-to-mid-20s reduce realized net revenue per unit. Persistent payer/utilization shifts compress margins, require higher gross sales to hit net targets, and materially weaken cash conversion and profitability prospects.
Binary Clinical Readout RiskAn upcoming blinded interim for IMpactMF in H2 2026 represents a binary, multi-year execution risk. A neutral/negative readout could slow adoption, hinder payer and regulatory negotiations, and materially reduce commercial upside and partnership prospects for imetelstat across indications.
Geron News
GERN FAQ
What was Geron Corporation’s price range in the past 12 months?
Geron Corporation lowest stock price was $1.04 and its highest was $2.01 in the past 12 months.
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is $827.56M.
When is Geron Corporation’s upcoming earnings report date?
Geron Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 2 days.
How were Geron Corporation’s earnings last quarter?
Geron Corporation released its earnings results on May 06, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.01.
Is Geron Corporation overvalued?
According to Wall Street analysts Geron Corporation’s price is currently Undervalued.
Does Geron Corporation pay dividends?
Geron Corporation does not currently pay dividends.
What is Geron Corporation’s EPS estimate?
Geron Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corporation have?
Geron Corporation has 641,521,000 shares outstanding.
What happened to Geron Corporation’s price movement after its last earnings report?
Geron Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went down -4.242%.
Which hedge fund is a major shareholder of Geron Corporation?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (181.69% Upside)
$4.00 (181.69% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Company Description
Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and commercial story: strong revenue growth (+31% YoY), expanding demand (+6% QoQ) and disciplined cost reductions position Geron to meet 2026 guidance. Important clinical and regulatory milestones (IMpactMF enrollment, NCCN order template inclusion, peer-reviewed publication) bolster the long-term value proposition. Key risks highlighted include widening gross-to-net pressure (21% vs 13% prior year), a meaningful quarter-over-quarter cash decline (~$60M) driven by one-time and supply investments, and unresolved European commercialization/pricing decisions. On balance, the favorable revenue trajectory, cost discipline and clinical progress outweigh the manageable near-term financial and market-access headwinds.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$4.00
▲(181.69% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
11.33% Mutual Funds
0.93% Other Institutional Investors
71.96% Public Companies and
Individual Investors